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Interstitial cystitis (IC), also known as painful bladder syndrome or bladder pain syndrome, is a chronic lower urinary tract syn-
drome characterized by pelvic pain, urinary urgency, and increased urinary frequency in the absence of bacterial infection or 
identifiable clinicopathology. IC can lead to long-term adverse effects on the patient’s quality of life. Therefore, early diagnosis 
and better understanding of the mechanisms underlying IC are needed. Metabolomic studies of biofluids have become a power-
ful method for assessing disease mechanisms and biomarker discovery, which potentially address these important clinical needs. 
However, limited intensive metabolic profiles have been elucidated in IC. The article is a short review on metabolomic analyses 
that provide a unique fingerprint of IC with a focus on its use in determining a potential diagnostic biomarker associated with 
symptoms, a response predictor of therapy, and a prognostic marker.
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INTRODUCTION
The main goal of this article is to provide the reader with an up-to-
date summary of the main metabolic variations taking place in 
biofluids with respect to interstitial cystitis (IC)/pelvic bladder 
syndrome/bladder pain syndrome as well as of the analytical strat-
egies employed to unveil urinary metabolomic biomarkers. 
  Metabolomics provides a global chemical fingerprint of the 
metabolism of cells and indicates physiological and pathological 
states of biological samples. Thus, the power of metabolomics 
allows unparalleled opportunity to query the molecular mecha-
nisms of the disease. Metabolites are not merely the end prod-
ucts of gene/protein expression; rather, they are the result of the 
interaction of the genome with its environment in the cells [1]. 
Thus, analyzing metabolic differences between pathological and 
normal conditions could provide scientific insight into the un-
derlying disease pathology. 
  Current metabolomics technologies may provide a compre-
hensive understanding of IC beyond the classical criteria, which 
are dependent on subjective observations. IC metabolomics 
provide the characteristics of the disease state and identify novel 
approaches to reduce clinical symptoms, including chronic blad-
der pain, a hallmark symptom of patients with IC. Despite the 
large number of review articles on metabolomics and its applica-
tion in cancer and diabetes research [2,3], there is no compre-
hensive review on metabolite profiling to study disease mecha-
nisms or biomarkers in IC. 
  Based on these current circumstances, we have organized this 
review article as follows. First, we present a short review on IC. 
Second, we discuss analytical techniques that are used in metab-
olomics, including computational methods for data processing. 
Next, we present an overview of the studies that have used me-
tabolomics to reveal IC metabolic fingerprints. Finally, we dis-
cuss the future research directions and summarize our findings.
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WHAT IS IC?
IC is characterized as a chronic bladder condition in which the 
disorder of the urinary bladder manifests as long-term symp-
toms that include urinary frequency/urgency or pain, pressure, 
discomfort, and nocturia. Chronic bladder pain is considered 
the hallmark symptom of patients with IC. Approximately 1 out 
of 77 people in the United States have been diagnosed with IC, 
and approximately 80% of patients are women [4,5]. IC has a 
long-lasting and adverse impact on the quality of life of patients, 
because IC suppresses physical function and social activity [4-6]. 
Its symptoms may be mild or severe and occasional or constant 
[7]. Many patients find that symptoms worsened with stress (ei-
ther physical or mental stress). The medical costs associated with 
IC has increased and is currently estimated to exceed $100 mil-
lion/yr in USA [8]. 
  Unfortunately, etiologies of IC are largely unknown. No effec-
tive treatment or prescription of medications has been clearly 
suggested. Additionally, the methods for accurate diagnosis of 
this condition have not been established thus far. Thus, physi-
cians are dependent on the inclusive and exclusive clinical diag-
nostic criteria based on National Institute of Diabetes and Diges-
tive and Kidney Diseases (NIDDK) guidelines (e.g., evaluation 
and treatment based on results from urinalysis, urine culture, 
cystoscopy, biopsy of the bladder wall and urethra, and bladder 
distention) [7]. The evaluation of the patient’s medical history, 
physical exam, and urine tests are needed for ruling out other 
conditions that might have caused similar symptoms.
  For IC diagnosis, the process from the first doctor’s visit to a 
definitive diagnosis in the urology clinic takes up a few years. 
The significant overlap between IC and other benign bladder 
dysfunction with similar urinary symptoms, including overac-
tive bladder, provides another challenge for IC diagnosis. A 
standard diagnostic test specific to IC has not yet been intro-
duced to the current clinical practice, and diagnosis is still de-
pendent on subjective criteria. Thus, the identification of bio-
markers of IC and the elucidation of the pathogenic mechanisms 
of biomarkers are clinical needs whose solution may lead to the 
discovery of new therapeutic approaches and biomarkers for 
better diagnosis of IC. 
  Efficient treatment regimens for IC have been another chal-
lenge to patients and urologists, which is also associated with the 
difficulty in diagnosis. Although there are multiple hypotheses 
about the primary cause of IC, the underlying pathologic mech-
anism remains completely undefined, which leads to delays in 
identifying effective therapeutic modalities. At this time, the 
Food and Drug Administration has approved only two treat-
ments for IC. One is oral pentosan polysulfate. The other treat-
ment is to place dimethyl sulfoxide into the bladder through a 
catheter. Another approach is to include procedures, such as hy-
drodistention, and oral pharmaceutical drugs, such as antihista-
mines, tricyclic antidepressants, and immune modulators. In 
general, symptom relief achieved with any of these strategies has 
been reported in only a small percentage of patients, and recur-
rence typically is evident within a few months [4,9]. For exam-
ple, antibiotics and pentosan polysulfate have been suggested to 
relieve the bladder pain or discomfort associated with IC; how-
ever, this treatment is only effective in relieving bladder pain in 
about 30%–60% of patients and it accompanies unfavorable side 
effects, including nausea, diarrhea, gastric distress, and hair loss. 
Moreover, while the mechanism of action of pentosan polysul-
fate in IC has been uncovered, the drug has anticoagulant and 
fibrinolytic effects. 
Attempts to Understand the Molecular Mechanism of IC 
Several abnormalities have been reported in epithelial, endotheli-
al, smooth muscle (detrusor), neuronal, or immune cells in IC 
patients. Bladder epithelium thinning, erosion, and increased in-
filtration of mast cells are some characteristics of IC histology, 
which suggest that the disease is mediated by a defect in the re-
generative potential of bladder epithelial cells and/or by immune 
impairment [4,5]. Furthermore, urothelium derived from IC pa-
tients exhibited suppressed cell proliferation and increased cell 
permeability [10-12], and these findings are supported at the 
molecular level in that the expression of proproliferative proteins 
(e.g., cyclin D1) and barrier tight junction proteins (e.g., zonula 
occludens-1, occludin, and claudin 1, 4, and 8) is dysregulated 
[11,12]. Bladder endothelium of IC often displays an increased 
level of platelet-derived endothelial cell growth factor/thymidine 
phosphorylase, vascular endothelial growth factor, and substance 
P expression [13-15] compared to those of controls. Notably, the 
IC bladder epithelial cells exhibited intrinsic alterations in differ-
entiation, neurotransmitter release, and potassium channel activ-
ity with elevated nitric oxide production, nuclear factor-κB acti-
vation, nerve fiber number, serum C-reactive protein [16], and 
neuropeptide Y and nerve growth factor production [16-18], 
suggesting the neural control of the urinary bladder [19].
IC Biomarkers Discovery 
Attempts to identify IC diagnostic markers have employed urine 108    www.einj.org
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cytology, cystoscopy with and without hydrodistention and/or 
bladder biopsy, and biofluid-based assays [7,20-22]. However, 
cytology is nondiagnostic. Cystoscopic observation is invasive, 
expensive, and painful. Cystoscopy cannot distinguish patients 
from normal since cystoscopic appearance is normal in the ma-
jority of IC patients [21]. The potassium sensitivity test is also 
used for diagnosis. It is based on the response of whether IC pa-
tients are more sensitive to the potassium solution than to water 
when placed in the bladder. However, the potassium test is pain-
ful and not specific to IC diagnosis [22]. Urodynamics evalua-
tion is another test; however, it is not necessary in all cases. 
  Metabolomics based on biofluids (including urine, plasma, 
saliva, fecal extract, and sputum et al.) have often been used to 
discover a noninvasive or minimally invasive biomarker test for 
other diseases, including cancer and diabetes [23]. In particular, 
assays of urine components are noninvasive and can be easily 
repeated, even by the patient. As one of many examples of uri-
nary IC biomarkers, a small glycosylated peptide, called an anti-
proliferative factor (APF), was originally identified and charac-
terized by Keay et al. [24] This short sialoglycopeptide consisting 
of 8 amino acids is 100% homologous to the putative sixth 
transmembrane domain of frizzled 8 (a Wnt receptor). Increased 
APF bioactivity is observed in urine specimens of IC patients. 
The measurement of APF in urine could segregate IC patients 
with 94% sensitivity and 95% specificity [25-27]. From in vitro 
systems, many reports, including those from our laboratory, 
demonstrated that APF regulates important signaling pathways, 
such as Akt, MAPK, β-catenin, or p53 signaling, leading to the 
suppression of proliferation of bladder epithelial cells and the in-
crease in transurothelial cellular permeability [24,28-30]. The 
global and unbiased APF signaling network was uncovered us-
ing a state-of-the-art quantitative proteomics method and a sys-
tems biology approach [28,30-33]. 
APPLICATION OF METABOLOMICS IN IC 
RESEARCH 
Metabolomic profiling, or metabolomics, is the systemic study 
of the unique small chemical fingerprints in a biological sample. 
The collection of small-molecule profiles represents the end 
products of cellular processes in biological systems (e.g., cells, 
tissues, or organs). A small amount of biofluid (urine, plasma, 
etc.) [23] allows for the characterization of hundreds of metabo-
lites that provides a functional readout of the metabolic state. 
Based on the accumulated knowledge-based database, metabo-
lite profiles can provide the biological interpretation of metabolic 
perturbations unique in IC patients [34]. In this section, we re-
view the current metabolomics techniques and analytical tools/
software for IC metabolic profiling.  
Techniques and Data Analysis of Metabolomics Data for IC
Analytical techniques 
NMR or MS?: Metabolomic studies typically begin with sample 
collection followed by sample analysis. A number of analytical 
techniques are currently used for metabolomic studies depend-
ing on the particular metabolite of interest. Nuclear magnetic 
resonance spectroscopy (NMR, in most cases 1H-NMR), gas 
chromatography-mass spectrometry (GC-MS), and liquid chro-
matography-mass spectrometry (LC-MS) metabolic techniques 
are widely used methods of analysis [35]. Much of the original 
metabolomics analyses were performed using NMR spectrosco-
py. Currently, chromatographic techniques, such as GC and LC 
coupled with MS (GS-MS and LC-MS), are used more. Fourier 
transform spectrometry [36] and capillary electrophoresis-MS 
[37,38] are also the major spectroscopic techniques used in me-
tabolomic analysis. 
  (1) NMR-based metabolomics analysis is robust and straight-
forward to implement. In particular, the reproducibility of NMR 
spectra is excellent [35], and NMR allows the easy identification 
of metabolites from 1-dimensional spectra. NMR is the best an-
alytical tool for urine and plasma analysis due to its nondestruc-
tive nature, minimum sample requirement, quantitative ability, 
and reliable metabolite identification that provides detailed in-
formation on the structure. However, NMR suffers from a lower 
sensitivity than MS [39], and compound identification is less 
straightforward compared to MS methods. 
  (2) MS-based metabolomics is more sensitive than NMR-
based metabolomics; however, it provides a higher risk of gener-
ating technical artifacts and measurement errors. MS is most of-
ten coupled to additional gas- or liquid-phase chromatography 
separation steps that allow for the stratification of complex mix-
tures. MS-based methods provide an overall large number of 
molecules that can be quantified. While sample preparation 
procedure for GC-MS, which includes extraction, drying, and 
concentration, is time-consuming, GC-MS is highly sensitive, 
reproducible, and cost-efficient. LC-MS also requires less com-
prehensive sample preparation than GC-MS. 
  There are advantages and limitations in the different metabo-
lomic methods. In general, MS involves the use of more com-
plex sample extraction methods, whereas NMR needs greater www.einj.org    109
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sample volumes. Both methods can provide identification of 
metabolites when their identity is initially unknown. These un-
knowns may eventually be identified using additional analytical 
methods, and thereby, can provide new insights into the pheno-
type or the disease [40]. Hence, a combination of different ana-
lytical techniques provides more information than a single tool 
when analyzing the complete metabolome.
Targeted or nontargeted?: Depending on the goal of the study, 
targeted or nontargeted metabolomics approaches may be se-
lected. Targeted approaches focus on only a specifically defined 
subset of metabolites. Targeted approaches are typically used to 
quantify the measured metabolites on an absolute scale by using 
external or internal standards as a reference, whereas nontarget-
ed approaches provide only semiquantitative measures, such as 
ion counts or areas under a curve using arbitrary units. Targeted 
methods with absolute quantification have the advantage in that 
measurements from different studies can easily be combined 
and compared. Targeted methods have lower technical variance 
since more time can be spent on measuring a smaller set of met-
abolic features. For the discovery of new processes and pathways, 
the use of nontargeted methods is recommended. By providing 
the widest possible range of metabolites, nontargeted metabolo-
mics approaches can reveal global profiles to discover new mole-
cules that are associated with the phenotype under investigation.
Data processing and metabolite identification: To identify the 
metabolites that are differentially expressed between the samples 
to possibly lead to biomarker selection, the large amount of data 
generated by this analysis should then be statistically processed. 
The key to identifying potential biomarkers is based on the dif-
ference in metabolite levels between the biological samples tak-
en from the IC patients and normal (control) subjects. 
  Several statistical tools are currently used to analyze NMR 
and MS-based metabolomics datasets, which include XCMS, 
MZmine, MetAlign, MathDAMP, and LCMStats. For NMR data 
analysis, the significantly altered NMR peaks can be identified 
by using a probabilistic approach called Bayesian Quantiﬁcation 
(BQuant) [39], which will allow the identification and quantifi-
cation of metabolites in local regions of the 1H-NMR spectra. 
For preprocessing of data from MS-based metabolomics data, 
XCMS software, a web-based integrated metabolomics analysis 
platform for the determination of metabolic profile differences 
and metabolite identification can be applied to reading, detec-
tion, and alignment. MetaboSearch software [41] could be used 
to perform mass-based metabolite identification simultaneously 
against the four major metabolite databases: the Human Metab-
olome DataBase (HMDB), Madison Metabolomics Consortium 
Database, METLIN (a metabolomics database), and LipidMaps. 
The ultimate output would reveal an extracted metabolite pro-
file. This can then be exported into software, such as MATLAB, 
for multivariate analysis to select metabolites that can further 
subdivide the IC from the controls [34].
  To elucidate the patterns and connections of the identified 
metabolites, a number of statistical algorithms for metabolomic 
data analysis could be applied both in a supervised and unsu-
pervised manner. The unsupervised methods that have been ex-
tensively used in metabolomic analysis are principal component 
analysis, hierarchical clustering, and self-organizing maps. Su-
pervised methods include analysis of variance, partial least 
squares (PLS), hierarchical PLS, k-nearest neighbors, and dis-
criminant function analysis. Using these methods samples can 
be clustered based on their metabolic fingerprints. Data integra-
tion and analysis is an important component of metabolomic 
studies, because a large amount of data is generated that is simi-
lar to proteomic and transcriptomic studies. The following data-
bases could be used: HMDB (http://www.hmdb.ca/), METLIN 
(http://metlin.scripps.edu/), MassBank (http://www.massbank.
jp), PubChem (http://ncbi.nim.nih.gov/), and Kyoto Encyclope-
dia of Genes and Genomes (http://www.kegg.jp/). To extract IC-
associated biological features and to identify the altered meta-
bolic pathways/networks in IC, intensive computational analyses 
for data integration with proteomics and genomics databases 
should be considered as described in our previous review [42]. 
  In summary, given that metabolomics also has potential utili-
ty in several fields of other diseases, including disease prognosis, 
diagnosis, and drug discovery and development, metabolic sig-
natures may serve as an alternative strategy for personalized 
therapy for IC patients with different phenotypes. The field of 
metabolomics may offer practical solutions to the challenges in 
IC research. Further research of the physiological change and 
mechanisms of IC requires more clinical data and powerful ana-
lytical strategies, especially structural identification techniques. 
Current Feature of Noninvasive Metabolomics for IC 
Diagnosis
As mentioned above, the best diagnostic would include a nonin-
vasive biomarker(s) test with high sensitivity and specificity. A 
non- or minimally invasive diagnostic method using biofluids 
(e.g., urine, blood, saliva, fecal extract, and sputum specimens) 110    www.einj.org
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may play a significant role in IC with regard to early detection, 
diagnosis, prognosis, drug development, and sensitivity predic-
tion to clinical treatments. 
  The most attractive biofluids in metabolomics are serum and 
urine [43-45]. Serum is a readily accessible and informative bio-
fluid, making it ideal for early detection of a wide range of dis-
eases. Monitoring of serum metabolites has several advantages 
due to its stability and less dilution effect [46]. Metabolite pro-
files of serum can be regarded as important indicators of physio-
logical and pathological states and may aid in the understanding 
of the mechanism behind disease occurrence and progression 
on the metabolic level.
  Urine is also an ideal bio-medium to study disease, because it 
is readily obtained and available with no required preparation by 
the patient, and it is less complex than other body fluids [47]. 
The ease of collection allows for serial sampling to monitor dis-
ease and therapeutic response. In terms of proteins and the 
prevalence of different cell types in blood, urine is much less 
complex, but nevertheless can contain disease biomarkers 
[4,6,23,48], specifically, excreted metabolites. Body fluids that 
are most proximal to a disease site can often provide a source of 
informative biomarkers [35,46,49]; therefore, urine-based diag-
nosis for IC is the most attractive strategy among other bioflu-
ids-based methods. However, analysis of urine samples poses 
several analytical challenges for metabolic profiling owing to 
wide variations in the ionic strength, pH, and osmolarity, partic-
ularly under conditions of physiological stress. Furthermore, 
urine samples typically have a huge dynamic range of metabolite 
concentrations and are subject to unpredictable dilution effects. 
Thus, to minimize artifacts arising from irrelevant biological 
variations, data can be normalized to creatinine concentrations, 
preferably by correcting volumes used for metabolomics assays 
instead of just correcting acquired data. Although creatinine is 
the best possible internal standard for correcting urine volume 
effects, creatinine levels can vary due to dietary intake and path-
ological conditions. Computational approaches for data normal-
ization methods can be applied to reduce artifacts due to sample 
variability using currently developed probabilistic quotient- and 
median-fold changes in normalization strategies [50,51]. 
  With the successful discovery of APF in IC patients’ urine 
[10,24], urine analysis has already had some success in studies of 
this condition. Metabolomics has demonstrated promise in the 
development of diagnostic tools for IC. Previously, a few at-
tempts to use metabolomics analysis to identify an IC signature 
have been published. 
  In 2003, Van et al. [52] has suggested that MS and NMR spec-
tral patterns can segregate patients with IC from non-IC patients, 
including bacterial cystitis (40 females and 10 males). Asymptom-
atic controls included individuals that were age-, race-, and gen-
der-matched to the IC patients (40 females and 10 males). Their 
NMR-based metabolomics analysis has identified 1,4-methyl-im-
idazole-acetic-acid and norepinephrine as potential diagnostic 
markers for IC. More recently, to distinguish the metabolites be-
tween patients with IC (n=10), those with bacterial cystitis 
(n=10), and healthy volunteers (n=10), Fukui et al. [53] has per-
formed a nontargeted analysis using ultraperformance liquid 
chromatography-time-of-flight/mass spectrometry-based metab-
olomics. They used 5 IC patients and 5 healthy volunteers as a val-
idation cohort. Their findings suggest that the urinary ratio of 
phenylacetylglutamine to creatinine can be correlated to the clini-
cal grade of IC (e.g., IC patients with mild (I/II) to severe (III) 
symptoms when compared to healthy volunteers). However, the 
mechanism of why urine specimens from IC patients have an in-
creased phenylacetylglutamine to creatinine is not well under-
stood. Additionally, this finding, while promising, is based on a 
small number of patients. A larger, prospective cohort-based vali-
dation is needed to translate this ratio to a clinical setting, which 
may help elucidate the mechanism governing IC initiation and 
progression. 
  Collectively, a workflow for IC metabolic profiling is suggest-
ed in Fig. 1. Researchers are also aware that the ability to obtain 
a high quality sample along with sample collection, storage, and 
analysis are important factors that have large consequences on 
metabolic results. This fact underscores the need for standard-
ized protocols. Recently the National Institutes of Health (NIH)/
NIDDK established the “Multidisciplinary Approach to the 
Study of Chronic Pelvic Pain” (MAPP) Research Network to 
better understand the pathophysiology of urologic chronic pel-
vic pain syndromes (including IC and chronic prostatitis/chron-
ic pelvic pain syndrome) and to provide a translational founda-
tion for the future clinical intervention and an improved clinical 
management. This ambitious NIH-funded, nationally wide 
project has collected a multisite and longitudinal biorepository 
of human specimens derived from men and women with IC as 
well as those from the age and gender-matched healthy controls 
using a standardized protocol through the phase I MAPP Net-
work [54,55].www.einj.org    111
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FUTURE STUDIES 
As a future direction, we may consider several studies that 
should soon be answered by metabolomics approaches. To iden-
tify metabolic signatures as predictive biomarkers of disease 
progression and its related comorbidities, metabolome assess-
ments need to be studied prior to disease onset and compared to 
metabolic changes during disease development. In particular, 
prospective studies can provide valuable insights into the mech-
anisms and processes altered during IC development and its co-
morbidities. Thus, this approach might be critical for biomarker 
discovery for IC. Currently, the most frequently applied drug 
and treatment for IC is pentosan polysulfate and hydrodisten-
tion, respectively. However, there are frequent recurrences with 
unfavorable side effects. Sensitivity prediction is a challenging 
task in the treatment of IC patients. Some patients with IC do 
not respond well to the current clinical therapies, and in some 
cases, therapies may cause severe toxicity and functional impair-
ment. Hence, it is crucial to phenotype individual patients with 
high responsiveness to treatment and to recommend personal-
ized therapy only for the selected patients. Altered metabolic 
profiles may be related to treatment response, and the perturba-
tion pattern indicates functionally relevant perturbations in me-
tabolism. The metabolite signature can also be used to identify 
mechanistic markers for drug or treatment response, which can 
then be used for screening and efficacy tests. For example, for a 
metabolic approach for responsiveness prediction to therapies, 
bio-specimens (such as urine or serum) could be used to derive 
metabolic profiles using NMR or MS-based metabolomics anal-
ysis. From the metabolic data, a proposed predictive model 
could be developed with high accuracy and sensitivity for me-
tabolites in IC, which can serve as a crucial modulator of IC re-
sponsiveness to clinical therapies. The prospective studies should 
attempt to recruit patients who are newly diagnosed with IC 
without previous treatment. This longitudinal sample collection 
for metabolic analysis should be thoughtfully collected under 
the standardized clinical protocol. Given that it is important to 
diagnose IC at an early stage to initiate appropriate therapy and 
improve the patient’s quality of life, future research need to con-
sider the following: (1) prospective studies to identify IC bio-
markers based on metabolite profiles; (2) dynamic metabolo-
mics analysis to determine the metabolites associated with 
symptom progression; and (3) metabolome perturbation and 
drug/treatment response (the identification of drug side effects 
and/or functional biomarkers for drug action).
CONCLUSIONS
IC, a debilitating chronic bladder disease, significantly reduces 
quality of life of women and men. Diagnostic and treatment 
modalities, even subjective diagnostic tools, are largely unavail-
able. Metabolomics analysis combined with computational ap-
proaches could provide a fingerprint of the metabolism of the 
disease and the essential molecular details about regulatory 
mechanisms. Metabolomics will lead to new insights into the 
perturbations leading to IC and other essential information for 
the goal of improving diagnostic capability and treatment strate-
gies for patients. 
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